Section 1c: FHIR®
Section 3: Implementation Guides
HL7 FHIR Implementation Guide: Profiles for ICSR Transfusion and Vaccination Adverse Event Detection and Reporting, Release 1 - US Realm
DESCRIPTION
The FHIR Implementation Guide provides a set of profiles for detection, validation, reporting, and ultimately recording/persisting Adverse Events associated with blood transfusions and vaccinations.
See the specification at www.hl7.org/fhir/us/icsr-ae-reporting/STU1
ALTERNATIVE NAMES
HL7 FHIR Implementation Guide: Profiles for ICSR Transfusion and Vaccination Adverse Event Detection and Reporting, Release 1 - US Realm may also go by the following names or acronyms:
"HL7 FHIR® IG: Transfusion and Vaccination Adverse Event Reporting, Release 1 - US Realm", ICSR AE Reporting
BENEFITS
- Facilitates electronic reporting of adverse events, and interoperability of data for patients experiencing these events
- Offers guidance on the data elements needed for detection, validation, and reporting of biologics-related adverse events, including data elements needed to capture the granular details of exposure to the suspect drug/biologic, along with documenting the adverse event/outcome associated with the suspect drug/biologic.
IMPLEMENTATIONS/CASE STUDIES
- IBM BEST C2 Project
- MedStar
RELATED DOCUMENTS
 |
HL7 FHIR Implementation Guide: Profiles for ICSR Transfusion and Vaccination Adverse Event Detection and Reporting, Release 1 - US Realm |
STU DOCUMENTS
|
HL7 FHIR Implementation Guide: Profiles for ICSR Transfusion and Vaccination Adverse Event Detection and Reporting, Release 1 STU 1- US Realm See the standard at http://hl7.org/fhir/us/icsr-ae-reporting/STU1. | (Submit Feedback on STU) |
TOPIC
- Public Health
BALLOT TYPE
- STU
STATUS DATE
2022-01-19RESPONSIBLE WORK GROUP
PRODUCT TYPE
- Implementation Guide
STAKEHOLDERS
- EHR, PHR Vendors
- Healthcare Institutions
- Pharmaceutical Vendors
- Regulatory Agency
FAMILY
- FHIR
CURRENT STATE
- Active
REALM
- US Realm